Design Therapeutics (DSGN) Consolidated Net Income (2020 - 2026)
Design Therapeutics (DSGN) posted quarterly Consolidated Net Income of -$23.4 million for Q2 2026, down 7.16% year-over-year from -$25.2 million in Q2 2025, and down 11.4% on a QoQ basis from -$21.0 million in Q1 2026.
Design Therapeutics (DSGN) Consolidated Net Income (2020 - 2026) Analysis & Trends
Design Therapeutics has reported Consolidated Net Income for 7 years, with the latest figure at -$23.4 million in Q2 2026.
- Consolidated Net Income for Q2 2026 came in at -$23.4 million, down 7.16% year-over-year; the trailing twelve-month figure through Jun 2026 was -$81.8 million (down 11.06% YoY), and the FY2025 annual result was -$53.8 billion, down 173.08% from the prior year.
- Consolidated Net Income slipped to -$23.4 million in Q2 2026, from -$21.0 million in the prior quarter.
- Over five years, Consolidated Net Income peaked at -$13.3 million in Q1 2024 and troughed at -$10.6 billion in Q4 2022.
- A 5-year average of -$606.8 million and a median of -$21.2 million in 2022 frame the typical range for Consolidated Net Income.
- The widest annual swing landed in 2022, when Consolidated Net Income slumped 92733.1%; it then soared 99.54% in 2023.
- A 5-year view of Consolidated Net Income shows it stood at -$10.6 billion in 2022, then soared by 99.54% to -$48.3 million in 2023, then jumped by 66.28% to -$16.3 million in 2024, then fell by 11.63% to -$18.2 million in 2025, then dropped by 28.61% to -$23.4 million in 2026.
- Per Business Quant data, the three most recent Consolidated Net Income figures were -$23.4 million in Q2 2026, -$21.0 million in Q1 2026, and -$18.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Design Therapeutics | 928.06 Mn | 720.67 Mn | - | -23.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -23.39 Mn |
| Mar 31, 2026 | -20.99 Mn |
| Dec 31, 2025 | -18.18 Mn |
| Sep 30, 2025 | -19.27 Mn |
| Jun 30, 2025 | -21.82 Mn |
| Mar 31, 2025 | -20.26 Mn |
| Dec 31, 2024 | -16.29 Mn |
| Sep 30, 2024 | -15.31 Mn |
| Jun 30, 2024 | -14.00 Mn |
| Mar 31, 2024 | -13.30 Mn |
| Dec 31, 2023 | -48.30 Mn |
| Sep 30, 2023 | -19.39 Mn |
| Jun 30, 2023 | -24.62 Mn |
| Mar 31, 2023 | -24.45 Mn |
| Dec 31, 2022 | -20.41 Mn |
| Sep 30, 2022 | -24.60 Mn |
| Jun 30, 2022 | -21.46 Mn |
| Mar 31, 2022 | -15.77 Mn |
| Dec 31, 2021 | -11.37 Mn |
| Sep 30, 2021 | -15.96 Mn |